Affymetrix, Partners HealthCare to develop microarray diagnostics

By Lisa Kerner

Charlotte, N.C., Sept. 7 - Affymetrix Inc. entered into a three-ear translational research collaboration with Partners HealthCare of Boston to develop microarray-based diagnostics for diseases such as newborn hearing loss, autism and hypertrophic cardiomyopathy.

Partners researchers at Harvard Medical School, Partners HealthCare and Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG) will create and validate microarray tests in Clinical Laboratory Improvement Amendments (CLIA) laboratories.

It could take a year to develop the first chip-based diagnostic test for use in HPCGG's CLIA-approved lab, according to Affymetrix and a HPCGG estimate.

Scientists will use Affymetrix GeneChip genotyping, resequencing and expression technologies to rapidly apply RNA and DNA patterns in tests to classify, manage and treat complex diseases.

CLIA-validated tests will be offered first to patients in the Partners HealthCare System.

Affymetrix is a medical technology company based in Santa Clara, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.